1173981-05-9

Basic information

• Product Name: [9-chloro-1-(4-bromo-2-methylphenyl)-1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazol-6-yl]methanol
• Synonyms: [9-chloro-1-(4-bromo-2-methylphenyl)-1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazol-6-yl]methanol
• CAS NO: 1173981-05-9
• Molecular Weight: 406.709
• Mol File: 1173981-05-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [9-chloro-1-(4-bromo-2-methylphenyl)-1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazol-6-yl]methanol(CAS DataBase Reference)
• NIST Chemistry Reference: [9-chloro-1-(4-bromo-2-methylphenyl)-1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazol-6-yl]methanol(1173981-05-9)
• EPA Substance Registry System: [9-chloro-1-(4-bromo-2-methylphenyl)-1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazol-6-yl]methanol(1173981-05-9)

Safety Data

• Hazardous Substances Data: 1173981-05-9(Hazardous Substances Data)

Upstream product

• 1173981-04-8 methyl 1-(4-bromo-2-methylphenyl)-9-chloro-1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazole-6-carboxylate 
• 1173983-84-0 methyl 3-amino-4-chloro-2-[(3-hydroxypropyl)amino]benzoate 
• 1173983-71-5 methyl 3-amino-2-[(3-hydroxypropyl)amino]benzoate 
• 1173983-70-4 methyl 2-[(3-hydroxypropyl)amino]-3-nitrobenzoate 
• 53553-14-3 2-chloro-3-nitrobenzoic acid methyl ester 
• 3970-35-2 2-chloro-3-nitrobezoic acid 

Downstream Products

• 1173981-06-0 9-chloro-1-(4-bromo-2-methylphenyl)-1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazole-6-carbaldehyde 
• 1173981-07-1 1-[1-(4-bromo-2-methylphenyl)-9-chloro-1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazol-6-yl]-2,2,2-trifluoroethanol 
• 1173981-09-3 9-chloro-6-[1-(difluoromethoxy)-2,2,2-trifluoroethyl]-1-(4-methoxy-2-methylphenyl)-1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazole 

Relevant articles and documents

Discovery of 1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles as novel class of corticotropin releasing factor 1 receptor antagonists

A new class of corticotropin releasing factor 1 (CRF1) receptor antagonists characterized by a tricyclic core ring was designed and synthesized. Novel tricyclic derivatives 2a–e were designed as CRF1 receptor antagonists based on con